Iovance Biotherapeutics, Inc.’s tumor-infiltrating lymphocyte (TIL) Amtagvi (lifileucel) scored a win in February as the first cell therapy to win US Food and Drug Administration approval for a solid tumor indication. In the years ahead, more TIL, T-cell receptor (TCR) and chimeric antigen receptor T-cell (CAR-T) therapies will likely hit the market. But while it appears the age of cell therapy for solid tumors has finally arrived, each modality faces unique challenges not associated with CAR-T therapies approved for blood cancers.
TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
